You may recall the intemperate remarks made by this fellow (and highlighted by our blog here, and here last year) -- at one point claiming that "Hep C had been cured for many years". And, to be clear, those statements were made before telaprevir and boceprevir had even been filed with FDA, for approval.
In any event, the Michigan-based publicly-traded multinational med-device maker, Stryker (think implants for joints, here), has put him in charge of international, basing him in Singapore -- from the story generated by their presser:
. . . .Stryker Corporation announced today the appointment of Ramesh Subrahmanian to the role of Group President, International, effective September 1, 2011. . . . Subrahmanian joins Stryker after twenty-three years in the pharmaceutical industry where he held a number of senior level leadership roles at Merck, Sanofi-Aventis and Hoechst Marion Roussel Ltd., most recently as Senior Vice President & President, Asia Pacific for Merck & Co. Inc. In his new role, he will have responsibilities for the Company's international business units and will be based in Singapore. . . .
Wild.
1 comment:
welcome back. Hope all is well.
BTW, you did see this:
http://www.fiercepharma.com/story/vertexs-incivek-could-top-1b-year-analyst-says/2011-08-19
What's more, the drug has gone on to outsell Merck's ($MRK) new hepatitis C treatment Victrelis at a 4-to-1 margin
Can't be good for Merck. Alas, where is dear ol'Freddie now?
It would be nice to ask him what went wrong.
Post a Comment